18 Dec 2018
Oral typhoid vaccine updated Summary of Product Characteristics (SPC)Vivotif® SPC updated to provide three years protection and minimum age for vaccination reduced to five years
The Summary of Product Characteristics (SPC) for oral typhoid vaccine, Vivotif® has been updated . In line with Public Health England’s ‘Green Book’ Immunisation against infectious disease, the Vivotif® SPC now indicates revaccination at three years for travellers at continued risk [1,2]. Previously Vivotif’s licence covered one year of protection for travellers.
The updated Vivotif® SPC now indicates vaccination for adults and children aged five years and older . Previously the marketing authority (licence) covered use in children from six years of age. Guidance on the use of Vivotif® in those aged five years is awaited from the Joint Committee on Vaccination and Immunisation.
Vivotif® vaccination is taken orally; the dose is one capsule taken on alternate days (three capsules in total). Each capsule should be taken with cold or lukewarm water (temperature not more than 37°C) on an empty stomach and at least one hour before the next meal . Note that the vaccine capsule should not be chewed and should be swallowed whole as soon as possible after placing in the mouth . This may be difficult for some young children.
Health professionals should ensure they are familiar with the Summary of Product Characteristics before prescribing the vaccine.